Clinical and molecular epidemiology of Escherichia coli sequence type 131 among hospitalized patients colonized intestinally with fluoroquinolone-resistant E. coli

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 7003-7006

  Han, Jennifer H ^a   Johnston, Brian ^b,c   Nachamkin, Irving ^a   Tolomeo, Pam ^a   Bilker, Warren B ^a   Mao, Xiangqun ^a   Clabots, Connie ^b,c   Lautenbach, Ebbing ^a   Johnson, James R ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN C; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; ACRAB-TOLC PROTEIN, E COLI; ANTIINFECTIVE AGENT; BACTERIAL DNA; CARRIER PROTEIN; ESCHERICHIA COLI PROTEIN; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CLINICAL FEATURE; CLONAL SPECIES; ESCHERICHIA COLI; ESCHERICHIA COLI SEQUENCE TYPE 131; FEMALE; FLUOROQUINOLONE RESISTANT ESCHERICHIA COLI; HOSPITAL PATIENT; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PREVALENCE; BACTERIUM IDENTIFICATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETICS; HOSPITALIZATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSMISSION;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CARRIER PROTEINS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84908451098     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03256-14     Document Type: Article

References (24)

1. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51:286-294. http://dx.doi.org/10.1086/653932.
2. Peirano G, Pitout JD. 2010. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 35:316-321. http://dx.doi.org/10.1016/j.ijantimicag.2009.11.003.
3. Rogers BA, Sidjabat HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 66:1-14. http://dx.doi.org/10.1093/jac/dkq415.
4. Lautenbach E. 2013. Flying under the radar: the stealth pandemic of Escherichia coli sequence type 131. Clin. Infect. Dis. 57:1266-1269. http://dx.doi.org/10.1093/cid/cit505.
5. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR. 2013. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among U.S. veterans. Clin. Infect. Dis. 57:1256-1265. http://dx.doi.org/10.1093/cid/cit503.
6. Nowrouzian FL, Adlerberth I, Wold AE. 2006. Enhanced persistence in the colonic microbiota of Escherichia coli strains belonging to phylogenetic group B2: role of virulence factors and adherence to colonic cells. Microbes Infect. 8:834-840. http://dx.doi.org/10.1016/j.micinf.2005.10.011.
7. Vimont S, Boyd A, Bleibtreu A, Bens M, Goujon JM, Garry L, Clermont O, Denamur E, Arlet G, Vandewalle A. 2012. The CTX-M-15-producing Escherichia coli clone O25b:H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 7:e46547. http://dx.doi.org/10.1371/journal.pone.0046547.
8. Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, Riddell K, Rogers P, Qin X, Butler-Wu S, Price LB, Aziz M, Nicolas-Chanoine MH, DebRoy C, Robicsek A, Hansen G, Urban C, Platell J, Trott DJ, Zhanel G, Weissman SJ, Cookson BT, Fang FC, Limaye AP, Scholes D, Chattopadhyay S, Hooper DC, Sokurenko EV. 2013. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J. Infect. Dis. 207:919-928. http://dx.doi.org/10.1093/infdis/jis933.
9. Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. 2013. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect. Control Hosp. Epidemiol. 34:361-369. http://dx.doi.org/10.1086/669865.
10. Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, Shih YC, Lin HH, Wang JL. 2012. Bacteremia caused by extended-spectrum-beta-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob. Agents Chemother. 56:618-622. http://dx.doi.org/10.1128/AAC.05753-11.
11. Lautenbach E, Fishman NO, Metlay JP, Mao X, Bilker WB, Tolomeo P, Nachamkin I. 2006. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. J. Infect. Dis. 194:79-85. http://dx.doi.org/10.1086/503046.
12. Lautenbach E, Metlay JP, Weiner MG, Bilker WB, Tolomeo P, Mao X, Nachamkin I, Fishman NO. 2009. Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance. Infect. Control Hosp. Epidemiol. 30:18-24. http://dx.doi.org/10.1086/592703.
13. Han JH, Nachamkin I, Tolomeo P, Mao X, Bilker WB, Lautenbach E. 2012. Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli. J. Infect. Dis. 206:1597-1603. http://dx.doi.org/10.1093/infdis/jis567.
14. White DG, Goldman JD, Demple B, Levy SB. 1997. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J. Bacteriol. 179:6122-6126.
15. Wang H, Dzink-Fox JL, Chen M, Levy SB. 2001. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob. Agents Chemother. 45:1515-1521. http://dx.doi.org/10.1128/AAC.45.5.1515-1521.2001.
16. Goering RV, Tenover FC. 1997. Epidemiological interpretation of chromosomal macro-restriction fragment patterns analyzed by pulsed-field gel electrophoresis. J. Clin. Microbiol. 35:2432-2433.
17. Clermont O, Bonacorsi S, Bingen E. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66:4555-4558. http://dx.doi.org/10.1128/AEM.66.10.4555-4558.2000.
18. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. 2009. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob. Agents Chemother. 53:2733-2739. http://dx.doi.org/10.1128/AAC.00297-09.
19. Clermont O, Lavollay M, Vimont S, Deschamps C, Forestier C, Branger C, Denamur E, Arlet G. 2008. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Chemother. 61:1024-1028. http://dx.doi.org/10.1093/jac/dkn084.
20. Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, Nordstrom L, Billig M, Chattopadhyay S, Stegger M, Andersen PS, Pearson T, Riddell K, Rogers P, Scholes D, Kahl B, Keim P, Sokurenko EV. 2013. The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio 4(6):e00377-13. http://dx.doi.org/10.1128/mBio.00377-13.
21. Banerjee R, Robicsek A, Kuskowski MA, Porter S, Johnston BD, Sokurenko E, Tchesnokova V, Price LB, Johnson JR. 2013. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-beta-lactamase-positive and -negative E. coli clinical isolates from the Chicago region, 2007 to 2010. Antimicrob. Agents Chemother. 57:6385-6388. http://dx.doi.org/10.1128/AAC.01604-13.
22. Hosmer DW, Lemeshow S. 1989. Applied logistic regression. Wiley and Sons, New York, NY.
23. Mickey RM, Greenland S. 1989. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 129:125-137.
24. Johnson JR, Nicolas-Chanoine MH, DebRoy C, Castanheira M, Robicsek A, Hansen G, Weissman S, Urban C, Platell J, Trott D, Zhanel G, Clabots C, Johnston BD, Kuskowski MA. 2012. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerg. Infect. Dis. 18:598-607. http://dx.doi.org/10.3201/eid1804.111627.